NASDAQ: NKTR

A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) is unfolding over alleged conflicts of interest and botched data analysis related to their partnership for the development of rezpegaldesleukin (REZPEG; NKTR-358), a first-in-class regulatory T (Treg) cell stimulator targeting the interleukin-2…